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Acute leukemia is the most common type of childhood and adolescence cancer, characterized by clonal proliferation of variably
diﬀerentiated myeloid or lymphoid precursors. Recent insights into the molecular pathogenesis of leukemia have shown that
epigenetic modiﬁcations, such as deacetylation of histones and DNA methylation, play crucial roles in leukemogenesis, by
transcriptionalsilencingofcriticalgenes.Histonedeacetylases (HDACs)arepotentialtargets inthetreatment ofleukaemia,and,as
aconsequence,inhibitorsofHDACs(HDIs)arebeingstudiedfortherapeuticpurposes.HDIs promoteorenhanceseveraldiﬀerent
anticancer mechanisms,such as apoptosis,cell cycle arrest, andcellular diﬀerentiation and,therefore, are in evidence as promising
treatment for children and adolescents with acute leukemia, in monotherapy or in association with other anticancer drugs. Here
we review the main preclinical and clinical studies regarding the use of HDIs in treating childhood and adolescence leukemia.
1.Introduction
Acute leukemia is a malignancy characterized by clonal
proliferation of variably diﬀerentiated myeloid or lymphoid
precursors.Itrepresentsthemostcommontypeofchildhood
and adolescence cancer, accounting for 32% of all tumours
diagnosed in children under15years ofageand 26% ofthose
diagnosed in adolescents under 20 years [1]. Over the past
few decades, the prognosis of children and adolescents with
acute leukemia has greatly improved, because of advances
in risk assessment, tailored chemotherapy, optimal recourse
to hematopoietic stem cell transplantation and innovative
supportive care [2]. The cure rates now exceed 80% for
children with acute lymphoblastic leukemia (ALL) and
50% for those with acute myeloid leukemia (AML) [3–5].
However, up to 20% of children with ALL and even more
children with AML relapse, and these patients eventually
present poor clinical outcome [6, 7]. Moreover a large
numberofpatientspresentsseveraltoxicsideeﬀectsresulting
from the very intensive chemotherapy [8]. Thus, novel
therapeutic approaches are needed to increase the cure rate
and the life’s quality of these young patients.
In the past decade the increased understanding of the
biology of acute leukemia,together with the implementation
of high-throughput genomic techniques, have led to the
development of molecular targeted therapies [9]. Epigenetic
modiﬁcations, such as deacetylation of histones and DNA
methylation, play crucial roles in the pathogenesis of many
cancers including leukemia, by transcriptional silencing of
critical genes [10]. The acetylation status of histones inﬂu-
ences the chromatin conformation and consequently the
transcription of genes. In normal cells there is a ﬁne balance
between acetylation and deacetylation of histones, depend-
ing on the activity of histone acetyl-transferases and histone-
deacetylase (HDAC) [11] being the alteration of these
enzymes possibly associated with tumorigenesis [12]. There
are18HDACsinhumans,11arezinc-dependentandfallinto
4classesonthebasisofhomologytoyeast HDACs;theothers
arenotzinc-dependentandnotinhibitedbycompoundsthat
inhibit zinc-dependent deacetylases [13]. HDACs has been
reported in association with acute promyelocytic leukemia
(APL) [14], and subsequently with many other hematologic
and solid tumours [15]. Several studies have shown aberrant
recruitment of HDAC-containing transcriptional repressor2 Journal of Biomedicine and Biotechnology
complexesbythefusion proteinsPML-RARαorPLFZ-RARα
and AML1-ETO in APL and AML, respectively, [16–19].
Furthermore, the constitutive upregulation of HOX genes
that characterized AML with the mutation of the MLL gene
has been shown to involve HDACs [20]. These observations
led to the identiﬁcation of HDACs as potential targets in
the treatment of leukaemia. As a consequence, inhibitors of
HDACs (HDIs) are being studied for therapeutic purposes,
in an eﬀort to upregulate the expression of the epigenetically
silenced genes, potentially modifying the leukemic pheno-
type. HDIs promote apoptosis, cell cycle arrest and cellular
diﬀerentiation, preventing malignant transformation [21,
22]. They are divided into several structural classes including
short-chain fatty acids (such as valproic acid and butyrates),
hydroximates (such as vorinostat and trichostatin-A), cyclic
tetrapeptides (such as trapoxin and depsipeptide), benza-
mides (such as MS-275) and many other compounds [23].
In the last few years, studies of HDIs have shown that histone
iperacetylation can be achieved safely in humans [21].
Thanks to the promising initial results obtained in adults
with myelodisplastic syndrome and acute leukemia [24, 25],
clinical trials are starting to involve pediatric patients too. In
the future the use of HDIs, in monotherapy or in association
with other anticancer drugs, could be a promising treatment
for children and adolescents with acute leukemia. Here we
review the main preclinical and clinical studies regarding the
use of HDIs in treating childhood and adolescence leukemia.
2.PreclinicalandClinicalTrials
Although only a few targeted agents are currently in general
use, the number of preclinical and clinical studies of HDIs
continue to grow. The trials of HDIs involving children
and adolescents with acute leukemia are reported below.
Molecule’s structures, chemical class of the molecules and
development status are resumed in Table 1.
Vorinostat (Suberoylamilide Hydroxamic Acid, SAHA). It is
a hydroxamic acid multi-HDI that blocks the enzymatic
activity of both Class I (HDAC1, -2, and -3) and Class II
(HDAC6) HDACs at low nanomolar concentrations (IC50 <
86nM) by directly binding to the catalytic site of these
enzymes [26]. The anticancer potential of vorinostat was
ﬁrst demonstrated in nude mice transplanted with human
prostate tumors [27]. Recently it has been approved by the
U.S. Food and Drug Administration for the treatment of
Cutaneous T-Cell Lymphoma (CTCL) and is now being
evaluated also in other hematological malignancies [28].
Through its inhibitory action on HDACs, vorinostat
has numerous eﬀects on biological processes including
cell cycle progression, apoptosis and diﬀerentiation at the
cellular level, as well as angiogenesis inhibition and immune
response modulation at the tissue level [26]. One model for
the antitumor action of SAHAis that its inhibition of HDAC
activity, andsubsequentaccumulationof acetylated histones,
leads to the activation of genes whose expression causes
induction of diﬀerentiation or apoptosis, thus inhibiting
tumor growth. This model is based on the ﬁnding that
the expression of a relatively small number of genes (2–10%
of expressed genes) is regulated following exposure of tumor
cells to vorinostat [26]. One of the most commonly induced
genes is the cyclin-dependent kinase inhibitor p21. However,
rather than promoting apoptosis in tumor cells, it appears
that vorinostat induced expression of p21 causes a cell
cycle arrest in a p53-independent manner [29]. Moreover,
increased acetylation of transcription factors such as p53,
HIF-1α, and E2F and increased acetylation of cytoplasmic
proteins such as α-tubulin, cortactin, and HSP90 also
contribute to vorinostat-induced cell cycle arrest, induction
of cell death, and the inhibition of tumor growth [26].
Using two NOD/SCID mouse models, Einsiedel et al.
demonstrated in vivo the eﬃcacy of vorinostat in B-cell pre-
cursors childhood ALL. In fact, vorinostat was administered
in a dose of 50, 100 or 150mg/kg, in both subcutaneous and
intravenous models, for 21 days and caused a clear growth
suppression of the xenograft tumors [30].
As a multi-HDI, vorinostat may be well-suited for
combination with other antineoplastic agents and radiation
therapy, due both to its relatively low toxicity to normal
cells and to its speciﬁc biological eﬀects on cellular pro-
cesses. Studies of the activity of vorinostat in combination
with other cancer therapies (including radiation, kinase
inhibitors, cytotoxic agents, and diﬀerentiating agents) have
shown synergistic and additive activity in a variety of
cultured human transformed cell lines [26]. Leclerc et al.
showed that coadministration of SAHA plus the highly
eﬀective antileukemic drug methotrexate (MTX) synergizes
to induce apoptotic death in ALL cells. When used as
single agents, both MTX and SAHA can induce cell death,
growth arrest and apoptosis, furthermore MTX plus SAHA
synergistically increase apoptotic cell death and decrease
viability in all B-precursor-ALL (SupB15, REH, NALM6,
RCH-ACV) and T-ALL (CCRF-CEM) cell models tested
[31]. Moreover, in vitro studies showed that SAHA causes
growth inhibition, apoptosis, and potentiates retinoic acid
induced diﬀerentiation in APL cells harboring t(15;17)
(NB4 cell line) and in BM cells from PLZF-RARα/RARα-
PLZF leukemic mice [32]. In the same study, He et al.
demonstrated for the ﬁrst time in vivo that SAHA induces
an accumulation of acetylated histones at a nontoxic dose
and, in combination with RA, prolongs survival and induces
complete remission in APL transgenic mice refractory to
retinoid acid treatment [32].
A phase I study of vorinostat in adult patients
with leukemias was recently reported [33]. Signiﬁcant
antileukemia activity was observed in patients with AML,
and vorinostat eﬀectivelyinhibited HDACactivity in periph-
eral blood and bone marrow blasts. Further phase I and
II trials of vorinostat as monotherapy or in combination
regimens in adult AML are ongoing [33]. Moreover, a phase
I study of vorinostat in pediatric patients with leukemia
or solid tumors has just been published [34]. The primary
purposes of this trial were to study the pharmacokinetics,
the maximum tolerated dose (MTD) and the side eﬀects of
vorinostat in young patients (from 1 to 21 years old) and
to determine the antitumor activity of SAHA administered
with or without 13-cis retinoic acid in these patients.Journal of Biomedicine and Biotechnology 3
Table 1: Main HDIs evaluated as emerging drugs for acute leukemias in pediatric and adult patients.
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This pediatric trial established the MTD of vorinostat as
230mg/m2/d administered orally in patients with recurrent
or refractory solid tumors, while patients with refractory
leukemia did not appear to tolerate this dose due to liver
dysfunction. Overall the authors pointed out that vorinostat
drug disposition and tolerance in children was similar tothat
observed in adult patients. Furthermore, other two phase II
studies are reported as currently recruiting participants. The
ﬁrst [35]isatrialstudyingtheeﬃcacyoftheuseofdecitabine
and vorinostat together with combination chemotherapy4 Journal of Biomedicine and Biotechnology
in treating patients with relapsed/refractory ALL or lym-
phoblastic lymphoma. They are recruiting patients from 2 to
60 years of age. The second study [36] is a clinical research
study whose aim is to ﬁnd the highest safe dose of vorinostat
that can be given in combination with idarubicin and ara-
C for the treatment of AML and high-risk MDS. They are
recruiting patients from 15 to 65 years of age.
Valproic Acid (VPA). It is a short-chain fatty acid that is a
weak HDI, but its long term availability as an antiepileptic
drug prompted its evaluation in oncology as an epigenetic
acting drug [28]. VPA can induce in vitro diﬀerentiation of
primary AML blasts [37] and seems to exert its anticancer
activity by inducing proteosomal degradation of HDAC,
in particular of HDAC2 [38]. Furthermore, in t(8;21)
AML, VPA might target AML1/ETO-driven leukemogenesis
through the disruption of aberrant HDAC1 function [19].
In fact, it has been reported that VPA treatment disrupts
the AML1/ETO-HDAC1 physical interaction, stimulates the
global dissociation of AML1/ETO-HDAC1 complex from
the promoter of AML1/ETO target genes, and induces a
signiﬁcant inhibition of HDAC activity, histone H3 and
H4 hyperacetylation, and recruitment of RNA polymerase
II, leading to transcriptional reactivation of target genes
otherwise silenced by AML1/ETO fusion protein. These
pharmacological eﬀects resulted in signiﬁcant antileukemic
activity mediated by partial cell diﬀerentiation and caspase-
dependent apoptosis [19]. Tonelli et al. showed that VPA
induces strong cell growth inhibition in MLL-AF9 AML-M5
cells (THP-1, MM6 and MOLM-13) and AML-M5 blasts
from a patient with a MLL gene rearrangement (MLL-
mut). This in vitro study indicated that VPA could activate
a p53-independent G1 cell-cycle arrest and apoptosis in
MLL-mut AML [39]. Also Einsiedel et al. demonstrated that
VPA inhibitsproliferation, inducesapoptosis and histone H4
hyperacetylation in BCP-ALL cell lines (Reh, Nalm6, Z33) in
vitro [30]. Moreover they showed that VPA administration
reduce the tumor growth signiﬁcantly in two NOD/SCID
mouse models of BCP-ALL. VPA treatment was able to
inhibit the leukemia-induced splenomegaly of animals after
intravenous challenge with ALL blasts, while no apparent
toxicity was detected [30]. Studies in mice with PML-RARα-
induced leukemia demonstrated that VPA treatment causes
upregulation of the death receptor proteins, TNF-related
apoptosis inducing ligand (TRAIL), Fas, Fas ligand and DR5
in cells treated with VPA [40]. Also primary human AML
samples that expressed neither PML-RARα nor AML-ETO
showed sensitivity to VPA and had increased apoptosis with
evidence of upregulated TRAIL, DR5, Fas and Fas ligand
levels in several cases that responded to HDAC therapy [40].
Several studies in vitro and in vivo showed that VPA is
more eﬃcacious in combination with other agents. Siitonen
et al. investigated the eﬀects of VPA as a single agent and
in combination with cytarabine (Ara-C) and etoposide in
an acute myeloblastic cell line (OCI/AML-2). They observed
a dramatic increase in cytotoxicity combining VPA with
Ara-C, whereas coaddition with etoposide had a much
smaller eﬀect on cell death. In addition, VPA induced
aclearG1phasearrest andup-regulatedcyclinD1expression
in the presence of Ara-C and etoposide [41]. Sanchez-
Gonzalez et al. studied the cellular and molecular eﬀects of
combining the anthracycline idarubicin with VPA in HL-
60 and MOLT4 cell lines [42]. Their results indicate that
the combination of an anthracycline with an HDI displays
as y n e r g i s t i ce ﬀect in vitro a n ds h o u l dh a v es i g n i ﬁ c a n t
clinical activity in patients with leukemia [42]. Antileukemia
activity has also been evaluated with VPA administered in
combinationwithhypomethylating agents.Thecombination
of 5-azacitidina (5-AZA), a hypomethylating agent with
signiﬁcant antileukemia activity in humans, with VPA was
studied in the leukemic cell lines HL-60 and MOLT4. It
showed a synergistic eﬀect in growth inhibition, induction
of apoptosis, and reactivation of protein p57 and p21 on
human leukemia cell lines, suggesting that the combination
of DAC and VPA could have signiﬁcant antileukemia activity
in vivo [43]. Several phase I/II studies of VPA monotherapy
or in combination have been completed in adult patients.
They include VPA plus decitabine [25], VPA plus retinoic
acid (ATRA) [44, 45], and VPA plus 5-AZA and ATRA
[46]. Garcia-Manero et al. conducted a phase 1/2 study
of the combination of decitabine and VPA in 54 patients
with advanced leukemia and a median age at diagnosis of
60 years [25]. An objective response was observed in 22%
patients, including 19% with a complete remission, and
the overall survival was 15.3 months. This study enrolled
also seven pediatric patients aged 4 to 21 years aﬀected
by relapsed/refractory AML. Although neither complete
nor partial remission was described, 3 patients achieved a
complete marrow response, and 1 patient presented only 6%
of marrow blasts. No pediatric cases presented signiﬁcant
toxicities related to therapy [25]. Soriano et al. conducted
a phase 1/2 study of the combination of 5-AZA, VPA and
ATRA in patients with AML or high-risk myelodysplastic
syndrome [46]. The trial involved a total of 53 patients with
a median age at diagnosis of 69 years. The combination
of the drugs resulted safe and active, with an overall
response rate of 42% and a median remission duration of
26 weeks. In their trial, Soriano and colleagues involved also
3 pediatric patients with recurring/refractory AML, and the
combination of 5-AZA, VPA and ATRA led to BM response
in 1 case [46]. Thus, combinationso fV P Aw i t h5 - A Z Ao r
decitabine and ATRA need to be further explored in speciﬁc
pediatric phase 1 studies in leukemia.
Entinostat (MS-275 or SNDX-275). It is a novel and
orally available synthetic benzamide HDI that preferentially
inhibits HDAC1, but does not possess activity against
HDAC6 [47]. Rosato et al. conducted a study on MS-275
in human leukemia cell lines (U937, HL-60, Jurkat, and
K562) and leukemic blasts obtained from the peripheral
blood of patients with AML. They demonstrated that MS-
275 exerts dose-dependent eﬀects on human leukemia
cells: a p21-dependent growth arrest and diﬀerentiation
at low drug concentrations and a marked induction of
ROS, mitochondrial damage, caspase activation, and apop-
tosis at higher concentrations [48]. One study exploredJournal of Biomedicine and Biotechnology 5
the eﬀect of MS-275 against a panel of leukemia cells of
human origin, each with deﬁned genetic alterations. MS-
275 signiﬁcantly induced growth arrest and apoptosis in the
AML cell line, MOLM13, and in the biphenotypic leukemia
cell line, MV4-11, which both possess an internal tandem
duplication mutation in the FLT3 gene. MS-275 induced
acetylation of HSP90 and ubiquitination of FLT3, which
hesitated in the degradation of FLT3 via the proteasome
pathway. Moreover, this study found that further inhibition
of MEK/ERK signaling potentiated the eﬀects of MS-275
in these cells. These results suggest that MS-275 may be
useful in treating leukemic patients with a mutation on
t h eF L T 3g e n e[ 49]. Another recent study showed that MS-
275 blocks Akt/mammalian target of rapamycin (mTOR)
signaling in AML HL60 and APL NB4 cells, inducing growth
arrest and diﬀerentiation. In addition, inactivation of mTOR
by rapamycin analog RAD001 (everolimus) signiﬁcantly
enhanced MS-275-mediated growth inhibition and apop-
tosis of these cells and potentiated the ability of MS-275
to induce the diﬀerentiation of HL60 and NB4 cells. These
results suggest that concomitant administration of an HDI
and an mTOR inhibitor may be a promising treatment
s t r a t e g yf o rp a t i e n t sw i t hA M Lo rA P L[ 50]. Moreover, MS-
275 might be used to enhance the antileukemic activity
of established nucleoside analogues such as ﬂudarabine.
In fact Maggio et al. examined the interaction between
M S - 2 7 5a n dﬂ u d a r a b i n ei nl y m p h o i da n dm y e l o i dh u m a n
leukemia cells and demonstrated that sequential treatment
of Jurkat lymphoblastic leukemia cells with MS-275 and
ﬂudarabineinducesmitochondrialinjury,caspaseactivation,
and apoptosis [51]. The antitumor eﬃcacy of MS-275 was
also evaluated in vitro in a series of pediatric solid tumor
cell lines, including neuroblastoma, rhabdomyosarcoma,
Ewing’s sarcoma (EWS), retinoblastoma, medulloblastoma,
undiﬀerentiatedsarcoma(US),osteosarcoma,andmalignant
rhabdoid tumors and in vivo using xenograft orthotopic
models of US, EWS, and neuroblastoma [52]. Jaboin et al.
showed that MS-275 treatment of pediatric tumor cell lines
induced the expression of p21 mRNA and diﬀerent eﬀects
on cell cycle, like apoptosis, while drug administration in
mice inhibited the growth of established tumors. Moreover,
a phase I and pharmacologic study of MS-275 in adults
with refractory andrelapsed acuteleukemiaswas reported by
Gojo et al. [53]. They observed that the maximum-tolerated
dose was 8mg/m2 weekly for 4 weeks every 6 weeks and
dose-limiting toxicities included infections and neurologic
toxicity manifesting as unsteady gait and somnolence. They
demonstrated that MS-275 eﬀectively inhibits HDAC in vivo
in patients, in fact the treatment induced an increase in
protein and histone H3/H4 acetylation, p21 expression, and
caspase-3 activation in bone marrow mononuclear cells.
Pivaloyloxymethyl Butyrate (AN-9). It is a relatively new
member of an established family of acyloxyalkyl ester
prodrugs of carboxylic acids that undergo rapid hydrolysis
and its anticancer eﬀect is assumed to stem primarily from
the release of butyric acid [54]. AN-9 induces acetylation
of histones at a concentration one order of magnitude
lower than butyric acid in vitro and this is most likely due
to its increased permeability across cell membranes [55].
Batova et al. investigated the in vitro therapeutic eﬃcacy
of AN-9 in HL-60 cell line and primary human acute
leukemiacells isolated from bone marrow and the peripheral
blood of pediatric patients with AML or B-precursor ALL,
including doxorubicin-resistant and/or clinically refractory
acute leukemias [54]. They demonstrated that AN-9 has
antiproliferative and cytotoxic eﬀects on all the leukemia
cells tested, including a doxorubicin-resistant T-ALL, a
clinically refractory relapsed AML, and a relapsed infant
ALL characterized by an 11q23 rearrangement and a very
poor prognosis. Furthermore, AN-9 is less toxic to nor-
mal hematopoietic progenitors and thus has selectivity for
leukemia cells, indicating that AN-9 is a selective anticancer
agent. The mechanism behind the antiproliferative eﬀect of
AN-9 appeared to be generally p21-independent and the
increased apoptosis was thought to be mediated through the
reduction in expression of the antiapoptotic bcl2 gene or
alternatively through the induction of genes involved in the
death receptor pathway [54]. Additionally, another advan-
tage of AN-9 is its ability to synergize with anthracyclines
such as daunomycin, commonly used in the treatment of
leukemia patients, allowing the use of a lower dose of this
drug and subsequently less toxicity. In fact Kasukabe et al.
demonstrated that AN-9 is an eﬀective antitumor agent in
mouse monocytic leukaemia Mm-A cells and in human
myeloid leukemia cell lines and that the administration of
AN-9 plus daunorubicin markedly prolongs the survival
of mice inoculated with Mm-A cells [56]. These several
studies demonstrated the selective toxicity of AN-9 to acute
leukemias, including drug-resistant relapsed leukemias, and
thus provide the rationale for the initiation of clinical trials
of AN-9 in acute leukemias of both adults and children.
Futhermore three clinical trials of AN-9 in adults with
othershematologic and solid tumourshave been terminated,
but the results have not yet been published. The ﬁrst is a
phase II study to assess the safety and eﬃcacy of AN-9 in
adult patients with chronic lymphocytic leukemia who have
relapsed or refractory disease after previous chemotherapy
treatment [57]. The second is a pilot phase I and II study of
AN-9 in adult patients with malignant melanoma who have
relapsed after treatment with chemotherapy or Interleukin-
2[ 58]. The last is a phase II comparative trial of AN-9 and
Docetaxel versus Docetaxel monotherapy in adult patients
with advanced nonsmall cell lung cancer [59].
Givinostat (ITF2357). It is a synthesized HDI containing
ah y d r o x a m i ca c i dm o i e t yl i n k e dt oa na r o m a t i cr i n g .I t
has been shown to inhibit the autonomous proliferation
of haematopoietic cells bearing the JAK2(V617F) mutation,
through a speciﬁc downmodulation of the JAK2(V617F)
protein and inhibition of its downstream signalling [60].
Recently a phase II study has been reported in adult
patientswithJAK2V617Fpositive chronic myeloproliferative
neoplasms [61]. Rambaldi observed that ITF2357 at doses
of 50mg twice daily was well tolerated and could induce
haematological response in most polycythemia vera and6 Journal of Biomedicine and Biotechnology
some myeloﬁbrosis in adult patients carrying the JAK2
V617F mutation. In addition a phase II study testing
givinostat in combination with hydroxyurea in a population
ofadultpatientswithJAK2V617Fpositive polycythemiavera
nonresponders tothe MTD of hydroxyurea monotherapy for
at least 3 months is recruiting patients [62]. Furthermore
ITF2357 was tested using an AML cell line as a model
and it showed selective low-dose antileukemic activity on
AML1/ETO-positive cells, emerging as a potent therapeutic
agent, particularly in AML1/ETO-positive cells [63].
Depsipeptide (Romidepsin, FK228). It is a cyclic peptide
that selectively inhibits HDAC isotypes 1, 2, 4 and 6
[28]. Recently it has been approved by the U.S. Food and
Drug Administration for the treatment of Cutaneous T-Cell
Lymphoma (CTCL) [64, 65] and is now being evaluated
also in other hematological malignancies. Preclinical studies
demonstrated that in vitro it inhibits HDAC in human
APL cell line NB4, furthermore in vivo administration of
depsipeptide alone partly inhibited the growth of established
tumors of NB4 subcutaneously transplanted in NOD/Shi-
scid/scid mice and its combination with ATRA was syn-
ergistically eﬀective in preventing leukemia death [66].
Depsipeptide was shown to inhibit HDAC in vivo in a
phase I trial in adult patients with AML: several patients
had evidence of antitumor activity following treatment, but
no partial or complete responses were noted. Moreover its
administration was limited by progressive adverse symptoms
that prevented repeated dosing [67, 68]. Therefore depsipep-
tide monotherapy appears to have limited clinical activity
both in adult and pediatric patients.
Mocetinostat (MGCD0103). It is an isotype-speciﬁc amino-
phenylbenzamide that inhibits HDAC isotypes 1, 2, 3 and 11
[69]. Preclinical studies have demonstrated that MGCD0103
is orally bioavailable with signiﬁcant in vitro antineoplastic
activity at submicromolar concentrations against a broad
spectrum of human cancers, including various leukemia
cell lines and xenografts [70]. A phase I study in adult
patients with AML demonstrated a favorable safety proﬁle
and showed activity as a single agent leading to a complete
bone marrow response [69].
Several other HDIs have shown promise in adults in
early phase I or small phase II trials. The hydroxamate
panobinostat (LBH589) has attractive preclinical and phase I
safety and eﬃcacy proﬁles, with evidence of activity in AML
[71]. Scuto et al. investigated the mechanism of action of
LBH589 in two Philadelphia chromosome-negative (Ph(-
)) ALL cell lines (T-cell MOLT-4 and preB-cell Reh). Low
nanomolar concentrations of LBH589 induced cell-cycle
arrest, apoptosis, and histone hyperacetylation. LBH589
treatment also increased mRNA levels of proapoptosis,
growth arrest, and DNA damage repair genes. This treat-
ment was active against cultured primary Ph(−)A L L
cells, including those from a relapsed patient, providing a
rationale for exploring the clinical activity of LBH589 in
treating patients with Ph(−)A L L[ 72]. A phase I study of
LBH589 has been reported in adult patients with refractory
hematologic malignancies [73]. Giles et al. observed that
intravenous administration of LBH589 was well tolerated at
doses <11.5mg/m2, while higher doses induced cardiac and
othertoxicitieslikenausea, diarrhea, vomiting,hypokalemia,
loss of appetite and thrombocytopenia. Overall the drug
treatment showed consistent transient antileukemic and
biological eﬀects that would be further explored using the
oral formulation of LBH589.
3.ConclusionsandPerspectives
Inrecentyears HDIshaveshown potentialanticanceractivity
against a variety of solid and hematologic tumors, included
leukemia. Vorinostat and depsipeptide have already been
approved by the U.S. Food and Drug Administration for the
treatment of cutaneous T-cell lymphoma [28, 65], and the
clinical use of HDIs in adults with leukemia may become
real in a short time. Several in vitro and in vivo studies
have been performed to test the role of HDIs in leukemia
treatments. The data from the adult trials show that HDIs, in
monotherapyaswellasincombinationtherapy,aregenerally
well tolerated. However, since there are very few patients
who have been treated for a long time, it will be necessary
to monitor long-term eﬀects in the future. However, the
available data support the rationale for using HDIs in the
treatment of childhood and adolescence leukemia. In the
last few years, clinical trials of these epigenetic modulators
have started to involve also children and adolescents aﬀected
by acute leukemia [25, 46]. Currently phase I-II clinical
trials are evaluating the eﬃcacy of vorinostat and VPA
in treatment of childhood and adolescent leukemia, alone
or in combination with other therapeutic agents [34–36].
In conclusion, further clinical trials involving HDIs are
needed to consolidate the clinical use of these agents in
both adult and pediatric acute leukemia. Moreover further
studies are needed to determine whether speciﬁc cytogenetic
or molecularly deﬁned subgroups can predict response or
resistance to HDIs therapy.
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